Drug Trial Radar · NCT05271370
An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
Last checked: Nov 19, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
56
Actual
Start
Aug 29, 2017
Primary completion
Jun 20, 2022
Study completion Jul 10, 2022
Sponsor
- Lead sponsor
- CytoDyn, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 2b/3 multi-center extension study designed to evaluate the long term antiviral activity, safety, and tolerability of the strategy of continuing PRO 140 350mg, 525mg, or 700mg SC (subcutaneous) monotherapy to maintain viral suppression after initial 48 weeks in virologically suppressed subjects. Consenting subjects will continue weekly PRO 140 350mg, 525mg, or 700mg monotherapy during the Treatment Extension Phase with the one-week overlap of existing retroviral regimen and PRO 140 350mg, 525mg, or 700 mg at the end of the treatment in subjects who do not experience virologic failure.
Conditions
- HIV-1-infection
Interventions
PRO 140 350Drug
Pro140 SC injection 350 mg
PRO 140 525Drug
525 mg
PRO 140 700Drug
700 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long Term Clinical Safety of PRO 140 Monotherapy by Assessing the Number of Participants With Grade 2, 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale, and the Number of Participants With Treatment-emergent Serious Adverse Events.Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
- Proportion of Participants Experiencing Virologic Failure for All Subjects Within Each Treatment Group.Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quest Clinical Research
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.